Significance of permanent atrial fibrillation in idiopathic dilated cardiomyopathy;Signification de la fibrillation auriculaire permanente dans la cardiomyopathie dilatée primitive

Annales de Cardiologie et d'Angeiologie

Volumn 56, Issue 3, 2007, Pages 107-110

  Brembilla Perrot, B ^a   Marcon O ^a   Chometon, F ^a   Groben, L ^a   Claudon, O ^a   Terrier de la Chaise, A ^a   Louis, P ^a   Blangy, H ^a   Sadoul, N ^a   Selton, O ^a   Ammar, S ^a   Abbas, M ^a   Juilliere Y ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

Atrial fibrillation; Dilated cardiomyopathy; Sudden death

Indexed keywords

ISOPRENALINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PROGNOSIS; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SYNCOPE; TREATMENT OUTCOME; AGED; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 34250190254     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2007.02.003     Document Type: Article

References (24)

1. Maisel W.H., and Stevenson L.W. Atrial fibrillation in heart failure epidemiology and rationale for therapy. Am. J. Cardiol. 91 (2003) 2D-8D
2. Kannel W.B., and Belanger A.J. Epidemiology of heart failure. Am. Heart J. 121 (1991) 951-957
3. Yamada T., Fukunami M., Shimonagata J., et al. Predicition of paroxysmal paroxysmal atrial fibrillation in patients with congestive heart failure. A prospective study. J. Am. Coll. Cardiol. 35 (2000) 405-418
4. Tuinenberg A.E., Van Gelder J.C., Brügermann J., et al. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart 82 (1999) 482-493
5. Crijns H.J., Tjeerdsma G., De Kam P.J., et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur. Heart J. 21 (2000) 1238-1245
6. Hsu L.F., Jaïs P., Sanders P., Garrigue S., Hocini M., Sacher F., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med. 351 (2004) 2373-2383
7. Reant P., Lafitte S., Jaïs P., et al. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation 112 (2005) 2896-2903
8. Gallagher M.M., Obel O.A., and Camm A. Tachycardia-induced atrial myopathy: an important mechanism in the pathophysiology of atrial fibrillation. Cardiovasc. Electrophysiol. 8 (1997) 1665-1674
9. Nerheim P., Birger-Botkin S., Piracha L., and Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110 (2004) 247-252
10. Brembilla-Perrot B., Suty-Selton C., Beurrier D., et al. Causes et prognostic des syncopes chez les patients avec une cardiomyopathie dilatée primitive. Arch. Mal Cœur 97 (2004) 1200-1205
11. Dries D.L., Exner D.V., Gersh B.J., Domanski M.J., Waclowin M.A., and Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction : a retrospective analysis of the SOLVD. J. Am. Coll. Cardiol. 32 (1998) 695-703
12. Wang T.J., Larson M.G., Lévy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their influence on mortality. The Framingham Heart Study. Circulation 107 (2003) 2920-2925
13. Olsson L.G., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular dysfunction. Results from the Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program. J. Am. Coll. Cardiol. 47 (2006) 1997-2004
14. Parkash R., Maisel W.H., Toca M., and Stevenson W.G. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am. Heart J. 150 (2005) 701-706
15. Hanna I.R., Heeke B., Bush H., et al. The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 47 (2006) 1683-1688
16. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 22 (2001) 1852-1923
17. Haegens V.E., Crijns H.G.M., Van Veldhuisen D.J., et al. for the RAte Control versus Electrical cardioversion for persisent atrial fibrillation study group. Rate control versus rhythm control. for patients with persistent atrial fibrillation with mild to moderate heart failure : results from the RAte Control versus Electrical cardioversion (RACE) study. Am. Heart J. 149 (2005) 1106-1111
18. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 107 (2003) 2926-2931
19. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 149 149 (2005) 548-557
20. Fung J.W., Yu C.M., Chan J.Y.S., et al. Effects of cardiac resynchronisation therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am. J. Cardiol. 96 (2005) 728-731
21. The AFFIRM. First antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation. An AFFIRM substudy of the antiarrhythmic drug. J. Am. Coll. Cardiol. 42 (2003) 20-29
22. Brembilla-Perrot B., Marçon O., Blangy H., et al. Incidence des tachycardies et tachyarythmies supraventriculaires dans les morts subites récupérées. Arch. Mal Cœur 99 (2006) 33-38
23. Stein K.M., Euler D.E., Mehra R., Deidl K., Slotwiner D.J., Mittal S., et al. Do atrial tachyarrhythmias beget ventricular tachyarrhythmias in defibrillator recipients?. J. Am. Coll. Cardiol. 40 (2002) 335-340
24. Deneke T., Lawo T., Gerritse B., Lemke B., and for the European GEM DR investigators. Mortality of patients with implanted cardioverter defibrillators in relation to episodes of atrial fibrillation.?. Europace 6 (2004) 151-158